Judicious use of low-dosage corticosteroids for non-severe COVID-19: A case report

Inflammation-mediated lung injury in severe cases of infection with SARS-CoV-2, the aetiological agent of Coronavirus disease 2019 (COVID-19), can lead to respiratory failure and death, and therapies that block or ameliorate lung injury-associated inflammatory “cytokine storms” and progression to ac...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhang Jian, Tian Zigang, Feng Lina, Yang Zhongming, Zou Bo, Li Kun, Zhang Yingliang, Wang Yaguo, Fleming Joy, Cui Wenyu
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	sars-cov-2 cytokine storm acute respiratory distress syndrome methylprednisolone personalized medicine Medicine R
Acceso en línea:	https://doaj.org/article/671b91315d4d43a8b36bb1ed9e874ba6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:671b91315d4d43a8b36bb1ed9e874ba6
record_format	dspace
spelling	oai:doaj.org-article:671b91315d4d43a8b36bb1ed9e874ba62021-12-05T14:10:54ZJudicious use of low-dosage corticosteroids for non-severe COVID-19: A case report2391-546310.1515/med-2021-0250https://doaj.org/article/671b91315d4d43a8b36bb1ed9e874ba62021-03-01T00:00:00Zhttps://doi.org/10.1515/med-2021-0250https://doaj.org/toc/2391-5463Inflammation-mediated lung injury in severe cases of infection with SARS-CoV-2, the aetiological agent of Coronavirus disease 2019 (COVID-19), can lead to respiratory failure and death, and therapies that block or ameliorate lung injury-associated inflammatory “cytokine storms” and progression to acute respiratory distress syndrome (ARDS) are urgently needed. Therapeutic use of corticosteroids for this purpose has been controversial because of conflicting reports on their efficacy and immunosuppressive behaviour. The WHO has strongly recommended treating critical COVID-19 patients with systemic corticosteroid therapy, but recommends against corticosteroid therapy in non-severe COVID-19 disease because of a lack of strong evidence on its efficacy. This retrospective case report describing the successful treatment of a non-severe COVID-19 case in Changchun, China, by judicious administration of corticosteroids using a personalized therapeutic approach was recorded to strengthen the evidence base showing how corticosteroid use in non-severe COVID-19 cases can be safe and efficacious. Alongside supportive care and lopinavir/ritonavir antiviral drugs, a low dosage of methylprednisolone was administered over a short period to attenuate lung inflammation. Regular chest CT scans guided dosage reduction in response to lesion absorption and improved lung condition. Judicious use of corticosteroids safely attenuated disease progression and facilitated rapid and complete recovery.Zhang JianTian ZigangFeng LinaYang ZhongmingZou BoLi KunZhang YingliangWang YaguoFleming JoyCui WenyuDe Gruyterarticlesars-cov-2cytokine stormacute respiratory distress syndromemethylprednisolonepersonalized medicineMedicineRENOpen Medicine, Vol 16, Iss 1, Pp 440-445 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	sars-cov-2 cytokine storm acute respiratory distress syndrome methylprednisolone personalized medicine Medicine R
spellingShingle	sars-cov-2 cytokine storm acute respiratory distress syndrome methylprednisolone personalized medicine Medicine R Zhang Jian Tian Zigang Feng Lina Yang Zhongming Zou Bo Li Kun Zhang Yingliang Wang Yaguo Fleming Joy Cui Wenyu Judicious use of low-dosage corticosteroids for non-severe COVID-19: A case report
description	Inflammation-mediated lung injury in severe cases of infection with SARS-CoV-2, the aetiological agent of Coronavirus disease 2019 (COVID-19), can lead to respiratory failure and death, and therapies that block or ameliorate lung injury-associated inflammatory “cytokine storms” and progression to acute respiratory distress syndrome (ARDS) are urgently needed. Therapeutic use of corticosteroids for this purpose has been controversial because of conflicting reports on their efficacy and immunosuppressive behaviour. The WHO has strongly recommended treating critical COVID-19 patients with systemic corticosteroid therapy, but recommends against corticosteroid therapy in non-severe COVID-19 disease because of a lack of strong evidence on its efficacy. This retrospective case report describing the successful treatment of a non-severe COVID-19 case in Changchun, China, by judicious administration of corticosteroids using a personalized therapeutic approach was recorded to strengthen the evidence base showing how corticosteroid use in non-severe COVID-19 cases can be safe and efficacious. Alongside supportive care and lopinavir/ritonavir antiviral drugs, a low dosage of methylprednisolone was administered over a short period to attenuate lung inflammation. Regular chest CT scans guided dosage reduction in response to lesion absorption and improved lung condition. Judicious use of corticosteroids safely attenuated disease progression and facilitated rapid and complete recovery.
format	article
author	Zhang Jian Tian Zigang Feng Lina Yang Zhongming Zou Bo Li Kun Zhang Yingliang Wang Yaguo Fleming Joy Cui Wenyu
author_facet	Zhang Jian Tian Zigang Feng Lina Yang Zhongming Zou Bo Li Kun Zhang Yingliang Wang Yaguo Fleming Joy Cui Wenyu
author_sort	Zhang Jian
title	Judicious use of low-dosage corticosteroids for non-severe COVID-19: A case report
title_short	Judicious use of low-dosage corticosteroids for non-severe COVID-19: A case report
title_full	Judicious use of low-dosage corticosteroids for non-severe COVID-19: A case report
title_fullStr	Judicious use of low-dosage corticosteroids for non-severe COVID-19: A case report
title_full_unstemmed	Judicious use of low-dosage corticosteroids for non-severe COVID-19: A case report
title_sort	judicious use of low-dosage corticosteroids for non-severe covid-19: a case report
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/671b91315d4d43a8b36bb1ed9e874ba6
work_keys_str_mv	AT zhangjian judicioususeoflowdosagecorticosteroidsfornonseverecovid19acasereport AT tianzigang judicioususeoflowdosagecorticosteroidsfornonseverecovid19acasereport AT fenglina judicioususeoflowdosagecorticosteroidsfornonseverecovid19acasereport AT yangzhongming judicioususeoflowdosagecorticosteroidsfornonseverecovid19acasereport AT zoubo judicioususeoflowdosagecorticosteroidsfornonseverecovid19acasereport AT likun judicioususeoflowdosagecorticosteroidsfornonseverecovid19acasereport AT zhangyingliang judicioususeoflowdosagecorticosteroidsfornonseverecovid19acasereport AT wangyaguo judicioususeoflowdosagecorticosteroidsfornonseverecovid19acasereport AT flemingjoy judicioususeoflowdosagecorticosteroidsfornonseverecovid19acasereport AT cuiwenyu judicioususeoflowdosagecorticosteroidsfornonseverecovid19acasereport
_version_	1718371608842731520

Judicious use of low-dosage corticosteroids for non-severe COVID-19: A case report

Ejemplares similares